Rizwan Romee MD

Hematologic Oncology

Associate Professor, Harvard Medical School, Dana Farber Cancer Institute

450 Brookline AveBoston, MA 02215
Phone+1 617-632-5138

Dr. Romee is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Romee's full profile Already have an account?

Summary

I am a cancer immunologist and the research focus of my lab is to engineer NK cells for enhanced targeting of advanced malignancies.

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Blood & Bone Marrow Transplant, 2011 - 2012
University of MinnesotaFellowship, Hematology and Medical Oncology, 2008 - 2011
University of MinnesotaResidency, Internal Medicine, 2005 - 2008
Government Medical College SrinagarClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2018 - 2027
MO State Medical License 2011 - 2019
MN State Medical License 2005 - 2008
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Modular), Allscripts, 2013-2014, 2017
CMS Meaningful Use Stage 1 Certification Follow My Health, Jardogs, 2013-2014, 2017
CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2013-2014, 2017

Clinical Trials

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Start of enrollment: 2013 Nov 11
COMPLETED
PHASE1, PHASE2
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
TERMINATED
PHASE1, PHASE2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
COMPLETED
PHASE2

Publications & Presentations

PubMed

Accelerating Translation of NK Cell Therapies to the Clinic: A European Perspective.
Lea Rebecca Knapp, Katharina Sophie Fischer, Janika Sosat, Jose Francisco Villena-Ossa, Pia Kluge
Human Gene Therapy. 2026-08-01
Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment.
Tereza Kochs, Pranay Nath, Alice Chen, Rizwan Romee, Andreia Maia
Advanced Science. 2026-06-01
Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.
Luis E Aguirre, Haesook T Kim, Hany Elmariah, Stacey M Frumm, Amar H Kelkar
Blood Advances. 2026-04-28

Journal Articles

The European Society for Blood and Marrow Transplantation (EBMT) Consensus Recommendations for Donor Selection in Haploidentical Hematopoietic Cell Transplantation
Leo Luznik, Karen Ballen, Asad Bashey, Hillard M Lazarus, Bipin N Savani, Rizwan Romee, Ephraim J Fuchs, Nature
Virescent Tongue
Rizwan Romee, Meagan Jacoby, Annals of Hematology
Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights fro...
Rizwan Romee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
Rizwan Romee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
Rizwan Romee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

New Cancer Therapies and Exercise Breakthroughs RevealedOctober 8th, 2025
CAR Natural Killer Cell Therapy Shows Promise in B-cell LymphomasJanuary 13th, 2025
NK Cells Show Promise Against Common Ovarian CancerJuly 13th, 2024

Grant Support

Microbial-based cancer therapy armored with membrane-bound cytokines for targeted immune modulation and safety-controlled deliveryUNIVERSITY OF MICHIGAN AT ANN ARBOR2026–2031